Advertisement
AXON vs BMRN
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. BioMarin Pharmaceutical (BMRN) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) delivered stronger year-to-date (YTD) returns of approximately 29%, outperforming BioMarin Pharmaceutical (BMRN)'s 9% amid recent market activity.
- AXON shares pulled back around 4% over recent weeks despite robust revenue growth projections and AI product launches.
- BMRN completed a $4.8 billion acquisition of Amicus Therapeutics, enhancing its rare disease drug portfolio.
- AXON's market capitalization of $32.6 billion dwarfs BMRN's $10.4 billion, reflecting differing scales in public safety tech versus biotechnology.
- Both stocks benefit from strong analyst sentiment, with AXON emphasizing AI-driven innovations and BMRN leveraging pipeline expansions.
- AXON trades at a high price-to-earnings (P/E) ratio of 264 versus BMRN's 30, highlighting growth premium trade-offs.
Introduction
This stock comparison examines AXON and BMRN, two growth-oriented companies navigating distinct sectors—public safety technology and biotechnology—in today's volatile market. Investors seeking relative performance insights, momentum plays, or diversification across tech innovation and healthcare may find value here. With AXON leveraging AI advancements and BMRN pursuing strategic acquisitions, this analysis highlights recent price behaviors, sentiment shifts, and key contrasts to inform stock comparison decisions.
AXON Overview and Recent Performance
Axon Enterprise (AXON), a leader in public safety solutions including conducted energy weapons (like TASER devices), body cameras, and cloud-based evidence management software, has integrated AI features such as virtual assistants and 911 call co-pilots. In recent market activity, AXON shares experienced a pullback of about 4% over the past month, trading around $405 after retreating from a 52-week high near $886. This follows strong fourth-quarter 2025 revenue of $797 million, up 39% year-over-year, driven by recurring annual recurring revenue (ARR) growth. Sentiment remains positive among analysts, who cite robust earnings projections ($1.66 EPS for the current quarter) and AI catalysts amid concerns over valuation and debt, influencing the stock's relative performance in recent weeks.
BMRN Overview and Recent Performance
BioMarin Pharmaceutical (BMRN) specializes in therapies for rare genetic diseases, with key products targeting conditions like phenylketonuria. Shares have traded in a 52-week range of $51 to $66, recently around $54, reflecting prolonged weakness despite YTD gains of 9%. Recent developments include the $4.8 billion acquisition of Amicus Therapeutics to bolster its pipeline and a board leadership transition. Fourth-quarter 2025 revenue reached $875 million, up 17% year-over-year, beating estimates, though earnings faced headwinds from inventory charges. Upcoming first-quarter 2026 results and analyst buy ratings have supported sentiment, countering sector pressures and peer declines in recent market activity.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots from its library of over 350 bots that trade thousands of tickers across various markets. Only 25 bots earn a spot in this trending section based on their suitability to current conditions, featuring impressive stats like annualized returns ranging from +24% to +164%, win rates of 51% to 88%, and profit factors up to 11.7. These bots employ diverse strategies—such as trend following, swing trading, and multi-agent AI with technical/fundamental analysis—across timeframes from 5 minutes to 50 days and sectors including semiconductors, AI infrastructure, and small caps. Traders can explore customizable signals with risk management like take-profit/stop-loss corridors to match their style. Visit Trending AI Robots for real-time insights and potential copy-trading opportunities.
Head-to-Head Comparison
AXON and BMRN contrast sharply in business models: AXON's hardware-plus-subscription ecosystem generates sticky recurring revenue in public safety, while BMRN relies on biotech drug pipelines vulnerable to clinical and regulatory risks. Growth drivers differ, with AXON fueled by AI expansions and law enforcement demand versus BMRN's acquisitions and rare disease approvals. Recent momentum favors AXON's YTD edge, though both face volatility—AXON from high valuation (P/E 264) and debt concerns, BMRN from trial discontinuations. Sector exposure pits industrial tech stability against biotech lumpiness, with market sentiment buoyed by analysts for both but AXON showing stronger trend consistency.
Tickeron AI Verdict
Tickeron’s AI tools currently lean toward AXON based on superior trend consistency, YTD relative performance, and AI catalysts positioning it favorably against BMRN's acquisition-driven stability. While BMRN offers value at a lower P/E and pipeline upside, AXON's growth metrics suggest higher probability of outperformance in the near term, contingent on market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and BMRN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBMRN’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BMRN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while BMRN’s TA Score has 6 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 5 bearish.
- BMRN’s TA Score: 6 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -5.91% price change this week, while BMRN (@Biotechnology) price change was -1.56% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -0.55%. For the same industry, the average monthly price growth was +14.74%, and the average quarterly price growth was +34.88%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.12%. For the same industry, the average monthly price growth was -0.84%, and the average quarterly price growth was +2342.61%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BMRN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Aerospace & Defense (-0.55% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+2.12% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BMRN | AXON / BMRN | |
| Capitalization | 35.7B | 10.8B | 331% |
| EBITDA | 320M | 482M | 66% |
| Gain YTD | -21.960 | -6.327 | 347% |
| P/E Ratio | 178.71 | 40.05 | 446% |
| Revenue | 2.98B | 3.24B | 92% |
| Total Cash | 737M | 2.22B | 33% |
| Total Debt | 1.83B | 1.44B | 127% |
AXON | BMRN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 65 | 100 | |
SMR RATING 1..100 | 82 | 87 | |
PRICE GROWTH RATING 1..100 | 60 | 53 | |
P/E GROWTH RATING 1..100 | 58 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (77) in the Biotechnology industry is in the same range as BMRN (82). This means that AXON’s stock grew similarly to BMRN’s over the last 12 months.
AXON's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for BMRN (100). This means that AXON’s stock grew somewhat faster than BMRN’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as BMRN (87). This means that AXON’s stock grew similarly to BMRN’s over the last 12 months.
BMRN's Price Growth Rating (53) in the Biotechnology industry is in the same range as AXON (60). This means that BMRN’s stock grew similarly to AXON’s over the last 12 months.
BMRN's P/E Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for AXON (58). This means that BMRN’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | BMRN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 62% | 1 day ago 65% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 55% |
| Advances ODDS (%) | 14 days ago 74% | 11 days ago 58% |
| Declines ODDS (%) | 4 days ago 69% | 5 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 71% | 6 days ago 57% |
Advertisement